Expanded Medicaid tied to more thyroid cancer diagnoses
Expanded Medicaid coverage was linked to the diagnosis of more thyroid cancer...Read more on AuntMinnie.comRelated Reading: Some cancers found earlier after Medicaid expansion Medicaid expansion tied to early breast cancer diagnosis Medicaid expansion under ACA linked to fewer cancer deaths Is thyroid cancer overdiagnosed for 9/11 first responders? Medicaid expansion boosted cancer screening rates (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2020 Category: Radiology Source Type: news

17.09.20: ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integ...
Source: Bayer IR Newsfeed: Events - September 17, 2020 Category: Pharmaceuticals Source Type: news

Cancer Incidence Up for Adolescents and Young Adults
2007 to 2016 saw increase in overall cancer incidence in all age groups, mainly driven by thyroid cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 17, 2020 Category: Cancer & Oncology Tags: Dermatology, Endocrinology, Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Nursing, Oncology, Pediatrics, Journal, Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

Congratulations to the winners of the Society ’s 2020 Journal Awards
The Society’s Journal Awards recognise articles from each of the Society-owned journals for excellence in both research focus and practice. Journal of EndocrinologyAndrogens modulate glucocorticoid receptor activity in adipose tissue and liver Dieuwertje C E Spaandermanet al. Journal of Molecular EndocrinologyCrosstalk of BMP-4 and RA signaling pathways on Pomc gene regulation in corticotrophs Leandro Nieto and Mariana Fuerteset al.Endocrine ConnectionsGenotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study Rui M B Maciel and Cleber P Camach et al.&am...
Source: Society for Endocrinology - September 14, 2020 Category: Endocrinology Source Type: news

08.09.20: Not intended for U.S. and UK Media
Bayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020Long-term efficacy and safety results for larotrectinib (Vitrakvi™) from an integrated data set of adult and pediatric patients with TRK fusion cancer, as well as sub-analyses in advanced thyroid and lung cancer patients / Tolerability and treatment response data from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Continued research to explore potential of marketed products, evaluating regorafenib (Stivarga™) and radium-223 dic...
Source: Bayer IR Newsfeed: Events - September 8, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Investor Update - September 7, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Media News - September 7, 2020 Category: Pharmaceuticals Source Type: news

Selpercatinib'Poised to Alter the Landscape' of RET+ve Cancers Selpercatinib'Poised to Alter the Landscape' of RET+ve Cancers
Selpercatinib induced high response rates in patients with RET-altered non-small cell lung cancer and medullary thyroid cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Many Thyroid Cancer Ultrasound Scans Unnecessary
Title: Many Thyroid Cancer Ultrasound Scans UnnecessaryCategory: Health NewsCreated: 8/25/2020 12:00:00 AMLast Editorial Review: 8/26/2020 12:00:00 AM (Source: MedicineNet Thyroid General)
Source: MedicineNet Thyroid General - August 26, 2020 Category: Endocrinology Source Type: news

Strong, durable responses to selpercatinib in RET-driven medullary thyroid cancer
(Massachusetts General Hospital) Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the gene RET, was effective in a clinical trial at shrinking tumors in patients with medullary thyroid cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 26, 2020 Category: Cancer & Oncology Source Type: news

Many Thyroid Cancer Ultrasound Scans Unnecessary
TUESDAY, Aug. 25, 2020 -- As many as one-third of doctors may be sending patients for a thyroid ultrasound for reasons not supported by guidelines, a new study finds. The use of ultrasound to detect thyroid cancer has led to a large increase in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 25, 2020 Category: General Medicine Source Type: news

Targeted Treatment Tied to Survival for Anaplastic Thyroid Cancer Targeted Treatment Tied to Survival for Anaplastic Thyroid Cancer
With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 21, 2020 Category: Surgery Tags: Hematology-Oncology News Source Type: news

What Are the Warning Signs of Thyroid Cancer?
Title: What Are the Warning Signs of Thyroid Cancer?Category: Diseases and ConditionsCreated: 8/14/2020 12:00:00 AMLast Editorial Review: 8/14/2020 12:00:00 AM (Source: MedicineNet Thyroid General)
Source: MedicineNet Thyroid General - August 14, 2020 Category: Endocrinology Source Type: news

What Happens to Your Body When You Have Thyroid Cancer?
Title: What Happens to Your Body When You Have Thyroid Cancer?Category: Diseases and ConditionsCreated: 8/14/2020 12:00:00 AMLast Editorial Review: 8/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 14, 2020 Category: Cancer & Oncology Source Type: news

Doctors order thyroid ultrasounds without good reasons
About one-third of physicians have ordered thyroid ultrasound scans for patients...Read more on AuntMinnie.comRelated Reading: Is thyroid cancer overdiagnosed for 9/11 first responders? Does thyroid cancer screening lead to overdiagnosis? CT radiation increases risk of thyroid cancer, leukemia AI boosts ultrasound for thyroid cancer screening New thyroid test could help patients avoid surgery (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 13, 2020 Category: Radiology Source Type: news

Some physicians are ordering thyroid tests for unsupported reasons
(Michigan Medicine - University of Michigan) Up to one-third of physicians reported sending patients for a thyroid ultrasound for reasons not supported by clinical care guidelines, a new study led by University of Michigan Rogel Cancer Center researchers finds. Routine use of ultrasounds to detect cancerous thyroid nodules have led to a significant increase in thyroid cancer cases in recent years, although many are low-risk and unlikely to cause serious harm. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 12, 2020 Category: International Medicine & Public Health Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

A Viewer Spotted a Lump on Her Neck. Now, She ’s Having a Tumor Removed.
Victoria Price, an investigative reporter in Tampa, Fla., said she was grateful that a viewer sent her a terse email suggesting that she get her thyroid checked out. (Source: NYT Health)
Source: NYT Health - July 25, 2020 Category: Consumer Health News Authors: Johnny Diaz Tags: Thyroid Cancer Neck Price, Victoria Television News and News Media Surgery and Surgeons Source Type: news

Comparing hyperthyroidism treatments with risk of cancer death
(JAMA Network) Researchers compared long-term risk of death from a solid cancer in patients treated with radioactive iodine, anti-thyroid drugs or surgery for hyperthyroidism. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 23, 2020 Category: International Medicine & Public Health Source Type: news

New special issue on hereditary endocrine tumours published in Endocrine-Related Cancer
The Society for Endocrinology journal,Endocrine-Related Cancer, has recently published a special issue on‘Hereditary endocrine tumours: Current state-of-the-art and research opportunities’. It is guest edited by Steven Waguespack and Constantine Stratakis, and contains eight free-to-read reviews covering topics such as: •New and future perspectives for parathyroid carcinoma•The state of science in medullary thyroid carcinoma: current challenges and unmet needs•Challenges and opportunities in genetic counseling for hereditary endocrine neoplasia syndromes• GPR...
Source: Society for Endocrinology - July 21, 2020 Category: Endocrinology Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other t...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - July 14, 2020 Category: Pharmaceuticals Source Type: news

Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
CAMBRIDGE, Mass., July 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 1, 2020 Category: Drugs & Pharmacology Source Type: news

3D ultrasound is effective for measuring blood flow
Researchers from across the U.S. confirmed the efficacy of 3D color-flow ultrasound...Read more on AuntMinnie.comRelated Reading: QT Ultrasound touts presentations on 3D ultrasound Researchers develop mini 3D ultrasound for scoliosis Automated 3D US effective for diagnosing hip dysplasia 4D ultrasound contrast HSG assesses fallopian tubes 3D tumor measurements on US spot thyroid cancer growth (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 30, 2020 Category: Radiology Source Type: news

Global Burden of Thyroid Cancer Is Increasing
TUESDAY, June 30, 2020 -- There is an increasing global burden of thyroid cancer, according to a study published online June 26 in JAMA Network Open. YuJiao Deng, Ph.D., from the First Affiliated Hospital of Zhejiang University Hangzhou, China, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2020 Category: Pharmaceuticals Source Type: news

Incidence of thyroid cancer has doubled globally, analysis finds
The number of people diagnosed with thyroid cancer has more than doubled worldwide since 1990, fueled by a rise in cases in Asia. The United States accounts for 10 percent of cases worldwide. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 26, 2020 Category: Consumer Health News Source Type: news

Trends in the global burden of thyroid cancer
This study examined the worldwide trends of thyroid cancer from 1990 to 2017 according to geographic location, sex, age and socioeconomic factors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 26, 2020 Category: Cancer & Oncology Source Type: news

$400,000 SBIR grant fast-tracks new approach to treating lung, thyroid cancers
(Purdue University) A $399,933 SBIR Phase I grant from the National Cancer Institute to KinaRx, a Purdue University-affiliated startup, will help to advance a novel platform aimed at producing more effective drugs to treat lung and thyroid cancers. The platform targets gene mutations that help cancers grow and expand within the body. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 19, 2020 Category: Biology Source Type: news

FDA Approves Keytruda for Certain Mesothelioma Patients
Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options. A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - June 17, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Thyroid Cancer Overdiagnosis Reaches Beyond Affluent Regions Thyroid Cancer Overdiagnosis Reaches Beyond Affluent Regions
Trends of over-screening seen in affluent economies appear to be spreading to middle-income countries as scanning becomes available.'In short, it is a global public health problem,'says author.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 9, 2020 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news

Fine-Needle or Core Needle Biopsy for Diagnosing FTC Fine-Needle or Core Needle Biopsy for Diagnosing FTC
When it comes to diagnosing follicular thyroid carcinoma, how do these two methods compare?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 9, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Obesity may not be associated with thyroid cancer risk
According to a study published inThe Journal of Clinical Endocrinology& Metabolism, obesity is not associated with an increased risk of developing thyroid disease or thyroid cancer.Endocrinology Advisor (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 4, 2020 Category: Endocrinology Source Type: news

RETEVMO (selpercatinib), FDA-Approved for Treatment of RET-driven Lung and Thyroid Cancers, Available at Biologics by McKesson
CARY, N.C., June 2 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Eli Lilly and Company as a specialty pharmacy provider for RETEVMOTM (selpercatinib), the first drug approved by the U.S. Food and Drug Administration (FD... (Source: McKesson News)
Source: McKesson News - June 2, 2020 Category: Information Technology Source Type: news

How Long Does Neonatal Galactorrhea Last?
Discussion Galactorrhea is a milky discharge from the breast in a non-lactating female. Neonatal galactorrhea is sometimes called “Witch’s Milk” based on ideas from the 17th century or earlier that witches would steal the milk for use in their magic. Infant breasts were often compressed to express the fluid and prevent its collection. During the 19th century, reports of breast inflammation and even abscess were reported because of this practice and it was strongly discouraged, and continues to not be recommended today. Enlargement of neonatal breasts and galactorrhea, both for males and females, is fel...
Source: PediatricEducation.org - May 25, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® ...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Retevmo for Certain Lung, Thyroid Cancers
Title: FDA Approves Retevmo for Certain Lung, Thyroid CancersCategory: Health NewsCreated: 5/11/2020 12:00:00 AMLast Editorial Review: 5/12/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 12, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves Retevmo for Certain Lung, Thyroid Cancers
MONDAY, May 11, 2020 -- Retevmo (selpercatinib) capsules have been approved to treat patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other thyroid cancers with an alteration in the " rearranged during... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 11, 2020 Category: General Medicine Source Type: news

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
Hematology/Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves Eli Lilly drug for thyroid, lung cancers driven by a genetic mutation
The U.S. Food and Drug Administration on Friday approved a drug to treat lung and thyroid cancers driven by a specific genetic mutation that Eli Lilly and Co acquired with its 2019 purchase of Loxo Oncology. (Source: Reuters: Health)
Source: Reuters: Health - May 9, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion
FDA approves Retevmo (selpercatinib) capsules to treat three types of tumors, non-small cell lung cancer, medullary thyroid cancer and other thyroid cancers, in patients whose tumors have an RET gene alteration. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 8, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Retevmo (selpercatinib) for Patients with Advanced RET-Driven Lung and Thyroid Cancers
INDIANAPOLIS, May 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg& 80 mg capsules), the first therapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 8, 2020 Category: Drugs & Pharmacology Source Type: news

Latest Clinical Trial for Pleural Mesothelioma Opens in Georgia
This study is open also to patients with lung cancer or urothelial cancer. In the trial, the use of cabozantinib will be combined with standard-of-care Alimta, the chemotherapy drug generically known as pemetrexed. The study is designed to establish a safe and effective dosage level for both agents when used together. Cabozantinib is known as an inhibitor. It blocks signals that encourage the growth of new blood vessels needed for cancer cells to divide and grow. Blocking those signals can shrink tumors or even cause tumor cell death, leading to significantly longer survival for patients. Cabozantinib will be taken orall...
Source: Asbestos and Mesothelioma News - May 6, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Dietary Inflammatory Index and Thyroid Carcinoma Risk Dietary Inflammatory Index and Thyroid Carcinoma Risk
Does diet-induced inflammation play a role in the development of differentiated thyroid cancer?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 5, 2020 Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news

Improving Risk Stratification in Papillary Thyroid Cancer Improving Risk Stratification in Papillary Thyroid Cancer
When it comes to the initial risk stratification of papillary thyroid cancer, which tool should be considered?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 28, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Thyroid Incidentalomas in Association With Low-Dose CT Thyroid Incidentalomas in Association With Low-Dose CT
Have incidental findings from low-dose CT scans performed for lung cancer screening contributed to an increasing incidence and overdiagnosis of thyroid cancer?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 22, 2020 Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news

Heightened Surveillance IDs More Thyroid Cancer in 9/11 Responders
TUESDAY, April 21, 2020 -- Excess asymptomatic thyroid cancer in Fire Department World Trade Center (WTC)-exposed rescue/recovery workers is apparently attributable to the identification of occult lesions during medical surveillance, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 21, 2020 Category: Pharmaceuticals Source Type: news

Is thyroid cancer overdiagnosed for 9/11 first responders?
Thyroid cancer diagnoses are up to three times more common in 9/11 first responders...Read more on AuntMinnie.comRelated Reading: Does thyroid cancer screening lead to overdiagnosis? CT radiation increases risk of thyroid cancer, leukemia AI boosts ultrasound for thyroid cancer screening New thyroid test could help patients avoid surgery US screening data from Fukushima shed light on thyroid cancer in kids (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 20, 2020 Category: Radiology Source Type: news